Related Experiment Video
Updated: Jul 15, 2025

Studies of Chaperone-Cochaperone Interactions using Homogenous Bead-Based Assay
Published on: July 21, 2021
An Unbiased Screen Identified the Hsp70-BAG3 Complex as a Regulator of Myosin-Binding Protein C3
Andrea D Thompson1, Marcus J Wagner2, Juliani Rodriguez1
1Department of Internal Medicine, Division of Cardiovascular Medicine, University of Michigan, Ann Arbor, Michigan, USA.
Insights
Familial hypertrophic cardiomyopathy (HCM) is linked to MYBPC3 gene variants. Researchers found that heat shock protein 70 and BAG3 regulate MyBP-C protein levels, offering potential therapeutic targets for HCM.
Area of Science:
- Cardiovascular Biology
- Molecular Medicine
- Genetic Cardiology
Background:
- Familial hypertrophic cardiomyopathy (HCM) is a primary genetic heart muscle disease.
- MYBPC3 gene variants are responsible for ~50% of familial HCM cases.
- Reduced levels of myosin-binding protein C (MyBP-C) are a hallmark of HCM caused by MYBPC3 variants.
Purpose of the Study:
- To identify novel pathways regulating MyBP-C protein homeostasis.
- To uncover potential therapeutic targets for HCM by understanding MyBP-C regulation.
Main Methods:
- Screened 2,426 bioactive compounds to identify modulators of MyBP-C levels.
- Utilized JG98, an allosteric modulator of heat shock protein 70 (HSP70).
- Investigated the role of HSP70-BAG3 complex in MyBP-C protein stability through genetic manipulation of BAG3.
Main Results:
- Identified JG98, which inhibits HSP70 interaction with BAG domain co-chaperones.
- Demonstrated that JG98 treatment reduces MyBP-C protein levels.
- Showed that genetic reduction of BAG3 mimics JG98 effects, decreasing MYBPC3 protein levels.
Conclusions:
- The heat shock protein 70-BAG3 complex is a novel regulator of MyBP-C protein stability.
- This finding provides a new understanding of MyBP-C homeostasis.
- Identified a potential therapeutic avenue for HCM by targeting the HSP70-BAG3 pathway.
Abstract:
Variants in the gene myosin-binding protein C3 (MYBPC3) account for approximately 50% of familial hypertrophic cardiomyopathy (HCM), leading to reduced levels of myosin-binding protein C3 (MyBP-C), the protein product made by gene MYBPC3. Elucidation of the pathways that regulate MyBP-C protein homeostasis could uncover new therapeutic strategies. Toward this goal, we screened a library of 2,426 bioactive compounds and identified JG98, an allosteric modulator of heat shock protein 70 that inhibits interaction with Bcl-2-associated athanogene (BAG) domain co-chaperones. JG98 reduces MyBP-C protein levels. Furthermore, genetic reduction of BAG3 phenocopies treatment with JG-98 by reducing MYBP-C protein levels.. Thus, an unbiased compound screen identified the heat shock protein 70-BAG3 complex as a regulator of MyBP-C stability.
More Related Videos
09:17Author Spotlight: Unraveling the Role of Myosin-7a and Usher Proteins in Hearing and Human Disease
Published on: August 23, 2024
10:24Defining Hsp33's Redox-regulated Chaperone Activity and Mapping Conformational Changes on Hsp33 Using Hydrogen-deuterium Exchange Mass Spectrometry
Published on: June 7, 2018
Related Concept Videos
Regulation of Nuclear Protein Sorting
Microtubule Associated Proteins (MAPs)
Overview of Myosin Structure and Function
Coat Assembly and GTPases
Coat assembly depends on the local availability of phosphatidylinositol phosphates or PIPs and GTP-binding proteins. Adaptor proteins, which link the coat proteins to the membrane, bind to these PIPs and play a crucial role in controlling...
Calmodulin-dependent Signaling
The Ca2+-CaM complex does not have enzymatic activity by itself. Instead, the complex binds downstream target proteins, including membrane proteins or enzymes,...
Energy to Drive Translocation
Generally, polypeptides are unfolded by two distinct...